Navigation Links
New discovery brings hope to treatment of lymphatic diseases
Date:8/10/2009

LEXINGTON, Ky. (Aug. 10, 2009) − Researchers in the laboratory of Dr. Jayakrishna Ambati at the University of Kentucky have discovered the first naturally occurring molecule that selectively blocks lymphatic vessel growth. In an article in the Aug. 9, 2009 online edition of Nature Medicine, they report the identification of a new molecule known as soluble VEGFR-2 that blocks lymphangiogenesis the growth of lymphatics but not blood vessel growth.

The twin circulatory systems of mammals - blood and lymphatic - are intricately intertwined, both anatomically and functionally. Until now it has been difficult to selectively target one without affecting the other. The lymphatic vessel network is essential for transporting fluids, molecules, and immune cells. It is crucial for wound healing and immune defense. Disturbances in the lymphatics are involved in diseases as varied as lymphedema, transplant rejection, and tumor metastasis, which collectively affect hundreds of millions of people worldwide.

This article, whose lead author is Dr. Romulo Albuquerque, currently a medical student in the UK College of Medicine, showed that soluble VEGFR-2 specifically blocks lymphatic vessel growth both during development and following injury by blocking VEGF-C, a powerful lymphatic growth factor. It also reports that loss of soluble VEGFR-2 during development led to the spontaneous invasion of lymphatic vessels, but not blood vessels, into the cornea, solving the long-standing mystery of why the cornea is normally devoid of lymphatics. Soluble VEGFR-2 was also required for normal development of lymphatics in the skin.

Importantly, administration of soluble VEGFR-2 to mice following corneal transplantation nearly eliminated graft rejection. This finding might also be applicable in kidney transplant rejection because it is known that lymphatic vessels are the culprit in the rejection of that organ as well. In addition, it challenges the prevailing dogma that abnormal blood vessels are responsible for transplant rejection.

The Ambati group also studied a childhood tumor known as lymphangioma, which is estimated to affect 1 in 50 babies and for which there is no satisfactory medical treatment. Administration of soluble VEGFR-2 blocked the growth of lymphangioma cells isolated from children with this tumor. Because this molecule spares blood vessels, it might offer a safer and more targeted treatment for this pediatric tumor. The potential benefit of modulating soluble VEGFR-2 in other diseases such lymphedema due to filariasis and or following surgery for breast cancer, as well as in tumor metastasis, are also under study.

"This paper by Dr. Ambati and his coworkers represents another in a line of highly novel and important findings from their laboratory," said Patricia A. D'Amore, Professor of Ophthalmology and Pathology, Harvard Medical School and Senior Scientist at the Schepens Eye Research Institute.

"The report of the first endogenous inhibitor of lymphangiogenesis is an exciting development and holds great therapeutic promise for a number of pathologies in which lymphatic growth is a serious complication."


'/>"/>

Contact: Ann Blackford
ann.blackford@uky.edu
859-312-3587
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Immune System Gene Discovery Sheds Light on Staph Infections
2. Cell Discovery May Bring Science Closer to Diabetes Cure
3. The Psychology of Frailty: An Identity Crisis Among the Elderly - Alzheimers Drug Discovery Foundations Dr. Howard Fillit to Co-Chair Symposium
4. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
5. Scientists Gather to Discuss Novel Uses of Caliper Life Sciences Discovery Platforms and Technology
6. Discovery Points to Regulation of Calcium Metabolism
7. IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program
8. Asthma Discovery May Lead to Better Treatments
9. Microsoft to Showcase Clinical Trial Solutions From Discovery to Approvals at Drug Information Associations 2009 Annual Meeting
10. Gaiam and Discovery Communications Announce Exclusive Licensing Deal
11. Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... Western University ... health and education to launch the University’s new Center for Innovation on Wednesday, September ... Health Education Center Lecture Hall 1, followed by a technology exhibition from 1 to ...
(Date:8/19/2017)... ... 2017 , ... President Donald Trump signed into law today ... greater public access to over-the-counter (OTC) hearing aids. , The measure enables adults ... being seen by a certified and licensed audiologist. , “The American Speech-Language-Hearing ...
(Date:8/19/2017)... ... August 19, 2017 , ... Curl Keeper® is excited to ... Curl Leaders, Editors’ Choice 2017 Award for the second year in a row. The ... and curlies alike was voted Best Moisturizer for Type 2 Wavies and Best Refresher ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, ... proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , ... energy to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:7/31/2017)... 31, 2017 Three Tru-D SmartUVC robots have arrived ... Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is a ... an environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs ... "Although the BAACH has a very ...
Breaking Medicine Technology: